The experimental protocol included the possibility of administrating methylene blue (MB) intravenous (IV) as a reducing agent to treat methemoglobinemia and reconvert the ferric heme of methemoglobin (Hb (Fe (III))) into the functional ferrous state Hb (Fe(II)) [87,88,89]. The gene discussed is GSTM1; the disease is methemoglobinemia.